key: cord-0864874-tt1sczw8 authors: Hoffmann, Markus; Hofmann-Winkler, Heike; Krüger, Nadine; Kempf, Amy; Nehlmeier, Inga; Graichen, Luise; Arora, Prerna; Sidarovich, Anzhalika; Moldenhauer, Anna-Sophie; Winkler, Martin S.; Schulz, Sebastian; Jäck, Hans-Martin; Stankov, Metodi V.; Behrens, Georg M.N.; Pöhlmann, Stefan title: SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination date: 2021-06-29 journal: Cell Rep DOI: 10.1016/j.celrep.2021.109415 sha: 723f06ecbac1e0f54846eba58bc203a513f80ffa doc_id: 864874 cord_uid: tt1sczw8 The emergence of SARS-CoV-2 variants threatens efforts to contain the COVID-19 pandemic. The number of COVID-19 cases and deaths in India has risen steeply and a SARS-CoV-2 variant, B.1.617, is believed to be responsible for many of these cases. The spike protein of B.1.617 harbors two mutations in the receptor binding domain, which interacts with the ACE2 receptor and constitutes the main target of neutralizing antibodies. Therefore, we analyze whether B.1.617 is more adept in entering cells and/or evades antibody responses. B.1.617 enters two out of eight cell lines tested with roughly 50% increased efficiency and is equally inhibited by two entry inhibitors. In contrast, B.1.617 is resistant against Bamlanivimab, an antibody used for COVID-19 treatment. B.1.617 evades antibodies induced by infection or vaccination, although less so than the B.1.351 variant. Collectively, our study reveals that antibody evasion of B.1.617 may contribute to the rapid spread of this variant. J o u r n a l P r e -p r o o f INTRODUCTION 49 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the For most cell lines we did not observe significant differences in cell entry efficiency 144 between the WT and variant S proteins (Figure 2A and Figure S1 ). The only exceptions were 145 Caco-2 and Calu-3 cells (and 293T cells in case of B.1.351), which are derived from human 146 intestine and lung, respectively, and for which the S protein of B.1.617 (and B.1.351 ) mediated 147 entry with moderately increased efficiency (Figure 2A and Figure S1 ). Of note this increase was 148 less prominent when Calu-3 cells were engineered to overexpress ACE2. In addition, we 149 investigated S protein-driven cell entry into BHK-21 cells, which were transfected either with 150 empty plasmid or ACE2 expression plasmid. As expected, BHK-21 cells transfected with empty 151 plasmid did not allow entry driven by any of the S proteins tested but were efficiently entered by 152 particles bearing the VSV glycoprotein (VSV-G) ( Figure 2B ). In contrast, directed ACE2 153 expression rendered these cells susceptible to S protein-driven entry and entry efficiency was 154 comparable between WT, B.1.351 and B.1.617 S proteins ( Figure 2B ). In sum, we demonstrate 155 that the S protein of SARS-CoV-2 B.1.617 allows for moderately enhanced entry into certain 156 cells of the respiratory and digestive tracts. 193 and it is believed that these antibody responses are important for protection from re-infection 194 (Rodda et al., 2021; Wajnberg et al., 2020) . Therefore, we determined whether variant B.1.617 195 evades inhibition by antibodies, which might contribute to its increasing transmission dynamics. For this, we analyzed antibody-mediated neutralization using plasma samples obtained from 15 197 COVID-19 patients at the intensive care unit of Göttingen University Hospital (Table S1 ). These Vaccination with Comirnaty/BNT162b2 has been shown to be safe and to protect against 210 COVID-19 with high efficiency (Polack et al., 2020) . The vaccine is based on an mRNA that address this question, we analyzed neutralization by 15 plasma samples obtained from vaccinees 217 two to three weeks after they had received the second vaccine dose. All sera efficiently inhibited 218 entry driven by WT S protein ( Figure 5B and Figure S3B ). Inhibition of entry driven by B.1.351 219 S protein was more than 11-fold reduced as compared to WT ( Figure 5B ), in keeping with domain. The location of the mutations in the context of the trimeric S protein is shown in the 341 lower panels. Color code: light blue, S1 subunit with RBD in dark blue; gray, S2 subunit; orange, 342 S1/S2 and S2' cleavage sites; red, mutated amino acid residues. Students t-test (p > 0.05, ns; p ≤ 0.01, **; p ≤ 0.001, ***). See also Figure S3 , Table S1 and 406 Table S2 . Caco-2 cells. In all cases, transduction efficiency was determined at 16-18 h postinoculation. For 564 this, the culture supernatant was aspirated. Next, cells were lysed in PBS containing 0.5% Triton-565 X-100 (Carl Roth) for 30 min at room temperature. Thereafter, cell lysates were transferred into 566 white 96-well plates. Finally, FLuc activity was measured using a commercial substrate (Beetle-567 Juice, PJK; Luciferase Assay System, Promega) and Hidex Sense Plate Reader (Hidex). The results presented in this study represent average (mean) data obtained from three biological Identification of SARS-CoV-2 spike 740 mutations that attenuate monoclonal and serum antibody neutralization Enhanced binding of the CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations Seroprevalence of SARS-CoV-2 in slums versus non-slums in 747 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus 756 by BNT162b2 vaccine-elicited human sera Broad and strong memory CD4(+) and CD8(+) T cells induced 759 by SARS-CoV-2 in UK convalescent individuals following COVID-19 Sensitivity of infectious SARS-CoV 1.1.7 and B.1.351 variants to neutralizing antibodies The variant gambit: COVID-19's next move Safety and Efficacy of the BNT162b2 mRNA 768 Covid-19 Vaccine Comparison of Four SARS-CoV-2 Neutralization Assays. Vaccines (Basel) Specific Immune Memory Persists after Mild COVID-19 Measuring SARS-CoV-2 776 neutralizing antibody activity using pseudotyped and chimeric viruses SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing 779 antibodies elicited by ancestral spike vaccines A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 Complete map of SARS-CoV-784 2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-Supasa Reduced neutralization of 788 SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera Detection of a SARS-CoV-2 variant of concern 791 in South Africa Effect of Dexamethasone on Days Alive 794 and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome 795 and COVID-19: The CoDEX Randomized Clinical Trial Weekly epidemiological update on COVID-19 -27 Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis CoV-2 infection persist for months